Lilly commences plaque psoriasis treatment head to head trial

Eli Lilly and Company (Lilly) has commenced the IXORA-R head-to-head (H2H) clinical trial to investigate the efficacy and safety of ixekizumab when compared to guselkumab to treat adult patients with moderate-to-severe plaque psoriasis. Roughly 960 patients are expected to be included in the 24-week, multicentre, randomised, blinded, parallel-group trial. The trial’s primary objective is the

Continue Reading

Enrolment completed for phase 3 of Horizon’s Tyroid eye disease trial

Horizon Pharma has stated that their Phase III trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED) has completed enrolment ahead of schedule. TED is a rare autoimmune disease where the insulin-like growth factor receptor (IGF-1R) is overexpressed on eye tissues, which then leads to local inflammation, orbital fibroblast proliferation and

Continue Reading

Clinical trials specialists: researchers of the future

Clinical Professionals are proud to be part of 2 trailblazer groups working on apprenticeship standards for clinical trials and regulatory affairs – now officially moving forward! More than 2,500 employers have developed apprenticeship standards, creating new opportunities and specialist on-the-job training programmes for the workforce of the future. The Clinical Trials Specialist Apprenticeship was the

Continue Reading